Updated:
Kamada Ltd.
Kamada is a publicly traded biopharmaceutical company headquartered in Rehovot, Israel, focused on plasma-derived protein therapeutics.
Kamada Ltd.
Kamada is a publicly traded biopharmaceutical company headquartered in Rehovot, Israel, focused on plasma-derived protein therapeutics. The firm markets a portfolio of approved products and maintains a development pipeline anchored by its inhaled AAT candidate for Alpha-1 Antitrypsin Deficiency. Kamada's strategy centers on a proprietary platform for extracting and purifying proteins from human plasma. The company serves the Alpha-1 deficiency and transplant-associated CMV markets with commercial products, and is advancing an inhaled formulation of AAT as a potential next-generation therapy. Its manufacturing operations are described as industry-leading, with a vertically integrated model spanning plasma collection through finished drug product. The firm operates from a single facility in Rehovot. Kamada has not disclosed total employees or investment professionals. It presents at medical conferences such as the WTC Transplant Summit 2025 (San Francisco, August 2–6, 2025). The company is publicly listed on the Tel Aviv Stock Exchange and the NASDAQ, and its shareholders include both institutional and retail investors. Kamada's structural differentiator is its focused specialization in plasma-derived biologics, a capital-intensive segment with high regulatory barriers. Rather than diversifying across modalities, the company concentrates on orphan and specialty indications where its plasma purification expertise provides a competitive advantage.
General information
Firm type
Public Company
Year founded
—
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Rehovot
Corporate office
Rehovot, Israel
Sector focus
Frequently asked questions
Who runs investment decisions at Kamada?
Kamada is a publicly traded company, not a family office. Investment decisions are made by its board of directors and executive management. The firm does not publicly name a single controlling principal or family foundation. (per company filings)
How does Kamada source proprietary deal flow?
Kamada is a biopharmaceutical company, not an investment firm. Its pipeline is primarily internally developed rather than sourced via external investments. The firm's competitive position rests on its plasma purification platform and approved products.
Is Kamada structured as a family office or a venture firm?
Neither. Kamada is a public biopharmaceutical company, traded on the Tel Aviv Stock Exchange and NASDAQ. It operates as a drug developer and manufacturer, not as an investment vehicle.
Does Kamada participate in fund commitments or only direct deals?
Kamada does not make fund commitments. As an operating company, its capital allocation focuses on R&D, manufacturing, and commercial activities in plasma-derived therapeutics.
What investment stages does Kamada typically target?
Kamada does not invest externally. It develops and markets its own proprietary therapeutics, with a pipeline ranging from preclinical through commercial-stage products.
Which sectors does Kamada explicitly avoid?
Kamada focuses solely on plasma-derived biologics. It does not participate in small molecules, gene therapy, or other modalities outside its core platform.
Where does the underlying wealth come from?
Kamada is a publicly traded company with no disclosed single-family wealth origin. Its shareholders are institutional and retail investors.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: